IGHV1OR16-2

Across TCGA patient cohorts, IGHV1OR16-2 RNA expression is significantly associated with the go_rna of many other GO terms, with 5,493 significant associations in total. HNSC shows the largest number of these associations.

The most reproducible IGHV1OR16-2-associated GO terms across cancer lineages are B cell mediated immunity, Immunoglobulin production, and Complement activation, classical pathway. Each is linked with IGHV1OR16-2 in more than 22 cancer types. Because this analysis shows association rather than direction, both IGHV1OR16-2-to-partner and partner-to-IGHV1OR16-2 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, B cell mediated immunity grouped by IGHV1OR16-2-low versus IGHV1OR16-2-high in SARC.

RNA expression associated GO terms by consensus

Ranked by combined sampling and lineage consensus. X-score (IGHV1OR16-2→partner) and Y-score (partner→IGHV1OR16-2) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner GO term	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
SARC	B cell mediated immunity →	+0.121	+0.058	<.001	.001	3	23
THYM	Immunoglobulin production →	+0.102	+0.063	<.001	.005	1	22
THCA	Complement activation, classical pathway →	+0.180	+0.110	<.001	<.001	3	20
SARC	Antibacterial humoral response →	+0.206	+0.057	<.001	.008	1	21
SARC	Lymphocyte costimulation →	+0.099	+0.060	<.001	.004	3	19
SARC	Regulation of B cell activation →	+0.074	+0.030	<.001	.009	2	20

Each partner links to its Q-omics profile. Showing the 6 strongest of 5,493 associations by consensus.

B cell mediated immunity by IGHV1OR16-2 expression — SARC

Explore this box plot interactively →